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This retrospective cohort study included all the subjects diag-
nosed with severe acute respiratory syndrome coronavirus 2 
infection (n = 2493) in 2 Italian provinces. Two hundred fifty-
eight persons died, after a median of 14.0 ± 11.0 days. Adjusting 
for age, gender, and main comorbidities, the ≥28-day case-
fatality rate did not decrease from March to April 2020 (ad-
justed hazard ratio, 0.93; P = .6).
Keywords.  case-fatality rate; COVID-19; lethality; SARS-
CoV-2; trend over time.
As of mid-July 2020, the severe acute respiratory syndrome co-
ronavirus 2 (SARS-CoV-2) pandemic has caused more than 
500  000 deaths worldwide [1], with largely discrepant case-
fatality rates across countries (from <1% to 16%) [2], likely due 
to differences in population age structure [3, 4], variations in 
testing policies and case recording [5], and/or preparedness of 
the healthcare system, which in turn is affected by the intensity 
of the spread [4, 5].
Since the start of the pandemic, Italy has been among the 
countries with the highest death toll, with approximately 35 000 
recorded deaths [1], and an estimated case-fatality rate of 14% 
[2], which peaked at 20% among the citizens aged ≥80 years [6].
In the last months, it has been suggested that SARS-CoV-2 
lethality may have decreased, mostly as a consequence of more 
tailored therapeutic approaches [7–11]. Although the claims 
were made by physicians actively engaged in the care of infected 
patients, the available evidence is anecdotal or based upon case 
studies.
In this study, we analyzed the data of all infected cases in 2 
Italian provinces to evaluate whether the SARS-CoV-2 case-
fatality rate decreased with time, adjusting for main potential 
confounders.
METHODS
This retrospective cohort study included all subjects with a 
diagnosed SARS-CoV-2 infection in the Provinces of Ferrara 
and Pescara, between March 3 (the onset date of the first cases) 
and May 3, 2020. All participants were followed up to May 31, 
2020. All infections were diagnosed by the central laboratories 
of Ferrara University Hospital or Pescara Hospital through 
reverse-transcription polymerase chain reaction (RT-PCR) test 
on nasopharyngeal swabs and were confirmed by the Italian 
National Institute of Health. Information on age, gender, and 
comorbidities were collected from local registries, clinical 
charts (for hospitalized patients), and through data-linkage 
with hospital discharge abstracts. To gather further informa-
tion on prior clinical history of the included subjects, the above 
records were further linked (through anonymized unique pa-
tient identifiers) with drug prescription datasets, which include 
all medicines prescribed by the Italian Health Service and dis-
pensed by both community and hospital pharmacies (known as 
“Ministry Records D and F”).
Electronic databases were queried from the day of the diag-
nosis until January 1, 2015. All data have been revised manually 
by 2 physicians (L.M. and M.E.F.), and the following conditions 
have been included in the analyses: hypertension, type II dia-
betes, major cardiovascular diseases (heart failure, myocardial 
infarction, and stroke—cardiovascular disease [CVD]), chronic 
obstructive pulmonary diseases ([COPD], bronchitis, pneu-
monia, asthma, and emphysema), cancers, and renal disease. 
No additional data were collected.
Patient Consent Statement
The study complies with the Declaration of Helsinki; the re-
search protocol was approved by the Ethics Committee of the 
Emilia-Romagna Region (code 287, approved on March 24, 
2020), and the requirement for informed consent was waived 
because of the retrospective and pseudo-anonymized nature of 
the data.
Data Analysis
We compared the case-fatality rate (fatal/confirmed cases) 
during the first 29  days after index day (from March 3 to 
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March 31, 2020)  with that of the second half of the period 
(days 30–63; from April 1 to May 3, 2020). For the sake of 
simplicity, the second period, composed by April and a few 
days of May, will be defined as “April.” The differences be-
tween the 2 periods were initially evaluated using t test for 
continuous variables and χ 2 test for categorical ones. The 
potential independent predictors of death were then evalu-
ated using Cox proportional hazards analysis (censoring at 
May 31, 2020 to include ≥28 days of follow up). The hazard 
ratio (HR) predicting the risk of death in April versus March 
was computed twice, either without or with an incorporated 
frailty term, to account for cluster-specific random effects 
potentially arising from the inclusion of cases diagnosed in 
2 different provinces. All covariates were included a priori in 
the model in their original form, with the exception of age, 
which was treated as either continuous or ordinal, to explore 
several age classes. Schoenfeld’s test was used to assess the va-
lidity of proportional hazards assumption, and Nelson-Aalen 
cumulative hazard estimates was used to check the validity of 
constant incidence ratios during follow up [12]. Censoring at 
28 days of follow-up, a random-effect logistic regression was 
also fit, with province as the cluster unit. The same above 
criteria were used to build the final model. Missing data were 
<5% in all primary analyses; therefore, no missing imputa-
tion technique was adopted. Statistical significance was de-
fined as a 2-sided P < .05, and all analyses were carried out 
using Stata, version 13.1 (2014; StataCorp, College Station, 
TX). The same analytical approach was adopted to assess a 
previous dataset [13], which was based upon samples col-
lected up to April 25, 2020 using a shorter, 10-day follow-up 
period.
RESULTS
The sample consisted of 2493 subjects (mean age 
58.6 ± 21.1  years; 47.7% males); 33.0% of them were hyper-
tensive, 13.0% were diabetics, and 15.5% had CVD; a total of 
914 subjects (36.7%) required hospital assistance. Some of the 
characteristics of the sample significantly varied from March to 
April 2020. Infected subjects were older by 3.1 years, and the 
proportion of females, diabetics, subjects with CVD, cancer, 
and renal diseases significantly increased (Table 1).
Overall, 258 persons died (247 during hospitalization), after 
a median of 14.0 ± 11.0 days of follow up: 157 (149 in-hospital) 
of the 1658 subjects diagnosed in March 2020 (9.5%), and 101 
(98 in-hospital) of the 835 subjects diagnosed from April 1 to 
May 3, 2020 (12.1%). The mean age of those who died sub-
stantially increased: it was 78.1 ± 11.0 for those diagnosed in 
March 2020, and 84.3 ± 10.2 for those detected in April 2020 
(P < .001). In March 2020, 33 of those deceased were younger 
than 70 years, and 10 were younger than 60 years. In April 2020, 
6 deaths occurred in subjects younger than 70 years (2 among 
those younger than 60 years).
As shown in Table 2, in the overall sample, the crude SARS-
CoV-2 lethality significantly increased from March to April 
2020 (from 9.5% to 12.1%; P = .042). The increase was signifi-
cant among the males (from 9.9% to 15.8%; P = .005) and those 
Table 1. Characteristics of the Sample, Overall and by Time of SARS-CoV-2 Infection Diagnosis After the First Case (March 3, 2020)
Characteristics Total Sample March 2020a April 1–May 3, 2020b Pc
 (n = 2493) (n = 1658) (n = 835)  
Mean age (SD), years 58.6 (21.1) 57.6 (19.5) 60.7 (24.0) <.001
Age-Class in Years, %     
 <18 3.6 3.1 4.4 .10
 18–39.9 15.1 14.2 16.9 .074
 40–49.9 14.5 16.1 11.3 .001
 50–59.9 17.6 18.8 15.3 .034
 60–69.9 16.1 19.0 10.4 <.001
 70–79.9 13.2 14.2 11.1 .031
 ≥80 19.9 14.6 30.5 <.001
Male gender, % 47.7 51.8 39.5 <.001
Hypertension, % 33.0 33.5 32.1 .5
Diabetes, % 13.0 11.3 16.2 .001
Major cardiovascular diseases, % 15.5 14.1 18.4 .004
COPD, % 5.1 5.4 4.7 .5
Cancer, % 7.1 8.0 5.4 .016
Renal diseases, % 5.3 4.3 7.4 .001
Hospital admission, % 36.7 37.8 34.4 .09
Abbreviations: COPD, chronic obstructive pulmonary disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SD, standard deviation. 
aFrom March 3 to March 31, 2020.
bFrom April 1 to May 3, 2020.








attolica del Sacro C
uore user on 12 O
ctober 2021
BRIEF REPORT • ofid • 3
without hypertension (from 4.4% to 6.7%; P = .040), diabetes 
(from 7.4% to 10.7%; P = .005), COPD (from 8.5% to 11.1%; 
P = .040), and cancer (from 8.7% to 11.3%; P = .050). No sig-
nificant change were observed among the other categories of 
subjects.
Multivariate Cox analysis did not confirm univariate results: 
adjusting for age, gender, hypertension, diabetes, CVD, COPD, 
cancer, and renal disease, the HR of death of those diagnosed 
in April 2020, compared with March 2020, was no more signif-
icant: 0.93 (95% confidence interval [CI], 0.71–1.21) (Table 2), 
and it did not change either including or excluding from the 
analyses the province of diagnosis. From March to April 2020, 
the risk of death did not significantly change in any subset of the 
sample, with the only exceptions of the females (adjusted HR, 
0.65; 95% CI, 0.44–0.95) and diabetics (adjusted HR, 0.57; 95% 
CI, 0.34–0.94), whose risk significantly decreased (Table 2). The 
results of the random-effect logistic regression did not vary: 
overall, the adjusted odds ratio of death at 28  days was 0.77 
(95% CI, 0.55–1.07; P = .12) for those diagnosed in April 2020, 
compared with the subjects detected in March 2020.
Table 2. Proportion of Deaths, Overall and by Time of SARS-CoV-2 Infection Diagnosis After the First Case (March 3, 2020), and Hazard Ratios Predicting 
the Risk of Death of Patients Diagnosed in April vs March 2020
Total Sample March 2020a April 1–May 3, 2020b Pc April vs March HR (95% CI) Pd
Overall 10.3 9.5 12.1 .042  0.93* (0.71–1.21) .6
     0.93** (0.71–1.21) .6
Age-Class in Years, %       
 <18 0.0 0.0 0.0 -- -- --
 18–39.9 0.3 0.0 0.7 .2 -- --
 40–49.9 0.6 0.8 0.0 .4 -- --
 50–59.9 2.1 2.6 0.8 .2 0.22 (0.02–2.05) .2
 60–69.9 6.7 7.3 4.6 .4 0.66 (0.22–1.99) .5
 70–79.9 18.8 19.1 18.3 .9 0.92 (0.52–1.63) .8
 ≥80 31.6 32.6 30.6 .6 0.94 (0.67–1.30) .7
Gender, %       
 Females 9.3 9.0 9.7 .7 0.65 (0.44–0.95) .027
 Males 11.5 9.9 15.8 .005 1.12 (0.77–1.61) .6
Hypertension, %       
No 5.2 4.4 6.7 .040 0.92 (0.58–1.45) .7
 Yes 20.9 19.6 23.5 .2 0.85 (0.61–1.19) .3
Diabetes, %       
No 8.3 7.4 10.7 .005 1.03 (0.75–1.42) .8
 Yes 24.2 27.7 19.3 .08 0.57 (0.34–0.94) .028
Major Cardiovascular Diseases, %       
No 7.1 6.7 7.9 .3 0.81 (0.57–1.16) .2
 Yes 27.9 26.2 30.5 .4 0.98 (0.65–1.48) .9
COPD, %       
No 9.3 8.5 11.1 .04 0.87 (0.65–1.16) .3
 Yes 28.9 27.0 33.3 .5 0.78 (0.37–1.63) .5
Cancer, %       
No 9.6 8.7 11.3 .050 0.84 (0.63–1.12) .2
 Yes 20.2 18.1 26.7 .2 0.89 (0.43–1.86) .8
Renal diseases, %       
No 9.3 8.6 10.9 .07 0.93 (0.70–1.24) .6
 Yes 28.6 29.6 27.4 .8 0.56 (0.27–1.15) .11
Presence of comorbidities, %e       
No 3.2 2.7 4.4 .078 1.23 (0.67–2.28) .5
 Yes 19.7 18.4 22.3 .14 0.93 (0.70–1.24) .3
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. 
The hazard ratios predicting the risk of death in April vs March was computed twice, adopting 2 separate models: in the first (*), a Cox proportional hazard analysis was performed; in the 
second (**), a frailty term was incorporated to the Cox model, to include cluster-specific random effects potentially arising from the presence of patients diagnosed in 2 different provinces.
aFrom March 3 to March 31, 2020.
bFrom April 1 to May 3, 2020.
cχ 2 test for categorical variables.
dCox proportional hazard model, adjusted for age, gender, hypertension, diabetes, major cardiovascular diseases, COPD, cancer, and renal disease. Some models could not be fit due to 
the scarce number of deaths.
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DISCUSSION
In this sample from 2 Italian provinces, after adjusting for 
several potential confounders, the SARS-CoV-2 case-fatality 
rate did not significantly decrease from March to April 2020, 
overall and in any age-class. The mortality trend throughout 
time was stable across all categories of risk, with the only 
exceptions of females and diabetics, both showing a sig-
nificantly lower death rate in April 2020, compared with 
March 2020.
Therefore, our data do not support the hypothesis of a de-
cline in SARS-CoV-2 lethality, which has been first suggested 
by some clinicians [7–11], after a reduction in the number of 
severe cases requiring hospitalization or intensive care unit 
support [14]. The above hypothesis has been recently propelled 
by the results of a study showing a reduced viral load during 
the latest phases of the pandemic in the nasopharingeal swabs 
collected from hospitalized patients in Northern Italy [15]. 
However, the available data were based on a limited number 
of subjects, and the correlation between viral load and clinical 
outcome of coronavirus disease 2019 (COVID-19) was almost 
entirely speculative [15].
Our data are in agreement with the officially available Italian 
data, showing a substantially stable raw case-fatality rate—ap-
proaching 13% during March and April 2020 [16]. A  study 
from a single Italian province found no significant change in 
COVID-19 lethality in the last considered week (March 23 to 
29, 2020), compared with the previous one (March 16 to 22, 
2020), although the lethality was lower than that of the very 
initial epidemic period (February 27 to March 15, 2020) [17]. 
However, it is notable that the follow up of the last considered 
week ended on April 3, 2020, thus lasting less than 14 days for a 
substantial proportion of participants.
It is worth considering that none of the potential explan-
ations to support a decline in virus lethality have been dem-
onstrated so far [18]: less virulent virus strains have not been 
reported [9]; none of the treatments that have been gradually 
administered to the study participants during the course of the 
pandemic (including antivirals, low molecular weight heparin, 
and monoclonal antibodies against inflammatory cytokines) 
has been proven effective to date [19, 20]; and finally, the health-
care system in the 2 provinces under study has never been over-
crowded during the pandemic [21].
The present data are updating a previous, preliminary 
analysis [13], significantly expanding the sample and length 
of follow up. Nonetheless, they require confirmation from 
larger datasets across multiple countries, comparing more 
distant time frames (because 1 month might be too short to 
detect substantial changes in healthcare system prepared-
ness and medical treatments) and accounting for additional 
potential confounders (such as body mass index—that we 
initially did not include among the variables to collect, but 
which later emerged as a significant predictor of death from 
COVID-19 [22, 23]—or data regarding acute physiology, 
organ damage, or vital signs observed among hospitalized 
subjects [24]) during time periods with a stable diagnostic 
capacity. In fact, in both of the selected regions, the number 
of RT-PCR tests increased substantially from March to April 
2020 (from a total of ≈500/daily to almost 6000/daily) [25, 
26], and it cannot be excluded that the proportions of un-
detected infections or unrecognized COVID-19 deaths were 
unbalanced over time. It should be noted, however, that in 
the regions under examination, the positivity rate slightly de-
clined throughout the time frame [26], which may likely re-
flect a consistent increase in the diagnostic capacity, in spite 
of the rise in the number of positive cases.
Another limitation of the present study is the lack of spe-
cific information on the treatments against COVID-19 ad-
ministered in hospital or prescribed at home. It is possible, or 
even likely, that the medical approach varied between March 
and April 2020, potentially impacting lethality. However, 
there is still scarce evidence of effectiveness for most of the 
treatments that were used in the selected periods (lopinavir/
ritonavir, hydroxychloroquine, and tocilizumab) [19, 20]. In 
addition, and more importantly, the evaluation of the poten-
tial motivations of the observed trend over time (including 
the impact of each risk factor or adopted treatment) was be-
yond the scope of the study, whose main aim was to describe 
whether a change in SARS-CoV-2 lethality occurred over 
time, regardless of any treatment, patient characteristic, of 
healthcare services change.
Male gender and some comorbidities were more frequent 
among the subjects infected in April 2020, which may have in-
creased the observed lethality. However, the case-fatality rates 
remained similar between March and April 2020 even when 
the sample was stratified for the presence of comorbidity, and 
these results were confirmed in multivariate analyses. It is worth 
noting that we relied on routinely collected hospitalization data 
to define comorbidities for nonhospitalized subjects (63.3% of 
the sample). Although this source of information may underes-
timate the prevalence of those comorbidities that rarely lead to 
hospitalization (such as mild COPD, hypertension or diabetes), 
we integrated these data (retrospectively collected up to 8 years 
before) with drugs prescriptions, which typically limit the in-
adequacy of disease burden estimates [17]. Indeed, collecting 
information on the clinical history registered before the epi-
demic onset may increase the accuracy of the data, because the 
experience with the early days of the pandemic suggests that the 
reliability of clinical history was limited, mainly due to critical 
patient conditions, common distance of relatives who could not 
confirm prior conditions, or lack of time to spend on clinical 









attolica del Sacro C
uore user on 12 O
ctober 2021
BRIEF REPORT • ofid • 5
CONCLUSIONS
Acknowledging these caveats, our data provide the most com-
prehensive evidence of a lack of a significant decrease of SARS-
CoV-2 case-fatality rate between March and April 2020, on a 
prospective sample, adjusting for several potential predictors of 
death. We trust that some of the many ongoing trials testing 
new therapies [27, 28]—starting from those reporting prom-
ising results on dexamethasone [29]—will determine a break-
through in the clinical course of the pandemic.
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